Steve Elms - 05 Mar 2026 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Reporting relationship: Director
Issuer ticker: ADMA
Reported as of: 05 Mar 2026
Net transaction value: +$217,420
SEC form: 4
Accepted by SEC: 09 Mar 2026, 09:14:42 UTC
Prior SEC filing: 11 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact

Key filing fact

Steve Elms filed Form 4 for ADMA BIOLOGICS, INC. (ADMA) on 09 Mar 2026.

Key facts

This page summarizes Steve Elms's Form 4 filing for ADMA BIOLOGICS, INC. (ADMA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 09 Mar 2026, 09:14.

Change

Previous filing in this sequence was filed on 11 Feb 2026.
Current net transaction value: +$217,420.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001250195 Primary reporting owner

ELMS STEVE

Relationship: Director
Address: C/O AISLING CAPITAL MANAGEMENT LP, 489 FIFTH AVENUE, 10TH FLOOR, NEW YORK
Signature: /s/ Steve Elms, by Michael A. Goldstein as Attorney-in-fact
Signature date: 09 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADMA transaction

Common Stock

Purchase

Transaction value: $109,690
Shares: +7,000
Change %: +0.34%
Price: $15.67
Shares after: 2,038,730
Date: 05 Mar 2026
Ownership: See footnote
Footnotes: F1, F2, F3

ADMA transaction

Common Stock

Purchase

Transaction value: $107,730
Shares: +7,000
Change %: +0.34%
Price: $15.39
Shares after: 2,045,730
Date: 06 Mar 2026
Ownership: See footnote
Footnotes: F2, F3, F4

ADMA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 98,020
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The reported transaction reflects the open market purchase of shares of ADMA Biologics, Inc. (the "Issuer") common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.58 to $15.74, inclusive.

Footnote F2

The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4.

Footnote F3

Includes (i) 2,031,730 shares owned by Aisling Capital II LP, which is a fund that was established in 2007 with a 10 year life ("Aisling Capital"), and (ii) 14,000 shares owned by Aisling Arcturus Partners, LP ("Aisling Arcturus" and, together with Aisling Capital, "Aisling"), of which 7,000 were purchased on March 5, 2026 and 7,000 were purchased on March 6, 2026. Mr. Elms is Aisling Capital's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of the Issuer's shares owned by Aisling and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.

Footnote F4

The reported transaction reflects the open market purchase of shares of the Issuer's common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.35 to $15.42, inclusive.

Footnote F5

Includes, as of the transaction date, (i) 10,690 restricted stock units granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 87,330 shares of common stock owned by the Reporting Person.